Rigel Pharmaceuticals, Inc. announced that new hires. Dana Pizzuti, who was Vice President of Regulatory Affairs at Gilead Sciences since 2007 and facilitated the approval of 40 new medicines during her tenure there, joins Rigel as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance. Dana brings tremendous experience across the broad range of regulatory, clinical, NDA and commercial-stage functions. Also joining the company is Giovanna Matthews. Most recently, she was CEO of LifeWatchCare/[indiscernible]Care. She joins Rigel as Executive Director, Market Access. And soon Sandra Tong will join as Vice President, Clinical Sciences and Drug Safety. Most recently, she was Vice President of Clinical Research at Plexxikon. Scott Henley has joined Rigel as Vice President, Clinical Operations. Previously, Scott was Vice President, Clinical Operations, at Titan Pharmaceuticals and has over 17 years of experience in this area.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.